Showing 1091-1100 of 3472 results for "".
Dr. Joel Schlessinger discusses the importance of clinical research in your practice
https://practicaldermatology.com/topics/practice-management/dr-joel-schlessinger-discusses-the-importance-of-clinical-research-in-your-practice/19135/With hundreds of new products, procedures and technologies becoming available every day, it is important to keep up with the changing medical world. One way to do this is through clinical research at your practice. In this video, Dr. Joel Schlessinger discusses how he began his clinical research stuTazarotene Lotion for Acne
https://practicaldermatology.com/topics/acne-rosacea/tazarotene-lotion-for-acne/23388/Tazarotene Lotion 0.045% offers dermatologists a new option that is effective and well tolerated for treating acne.Physician Spotlight: Sue Ellen Cox, MD
https://practicaldermatology.com/columns/physician-spotlight/physician-spotlight-sue-ellen-cox-md/23966/Teledermatology Update
https://practicaldermatology.com/topics/practice-management/teledermatology-update/20146/Many dermatologists and dermatologic surgeons adopted teledermatology or began to use it more frequently throughout the COVID pandemic. Many consultations and post-operative follow-up appointments were handled through telemedicine platforms. Anthony Rossi, MD talks about the benefits of this technolDermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesDermWireTV: AcneAlly Launches, Rosacea Insights, MC2/EPI Collaboration
https://practicaldermatology.com/series/dermwire-tv/dermwiretv-acneally-launches-rosacea-insights-mc2epi-collaboration/19849/Dennis Porto, MD and Riyaz Farhaad, MD have launched AcneAlly.com, an online service that allows patients access to a board certified dermatologist and a standardized approach to assessment and long-term monitoring. Julie Harper, MD discusses findings from “Beyond the visible: Rosacea and psoriasisBlinded by the Light—and More
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/blinded-by-the-lightand-more/23154/CSF faculty members share their favorite Energy- and Light-Based Devices.DermWireTV: Noble Educates on Self-Injection; AAD and DEF Meeting Updates
https://practicaldermatology.com/topics/practice-management/dermwiretv-noble-educates-on-self-injection-aad-and-def-meeting-updates/19645/Participants in a study by the company Noble show that the vast majority of patients—92%—would prefer to bring home a training device to practice with prior to starting self-injection. Noble creates trainers for autoinjectors intended to increase patient confidence and autonomy with self-managed treSkin Cancer Awareness, Epiduo Data, Impoyz Launch
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-skin-cancer-awareness-epiduo-data-impoyz-launch/18307/Data shed light on patents' attitudes towards kids' sunblock and new findings emerge on melanoma risks. FDA accepts BLA for cemiplimab for advanced SCC and approves Novartis' Tafinlar in combination with Mekinist for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutationsJoel Schlessinger MD Discusses Personal Phones in the Office
https://practicaldermatology.com/topics/practice-management/joel-schlessinger-md-discusses-personal-phones-in-the-office-/19276/Dealing with personal phone use at work is an issue that almost every business must consider. While it is important that people are available in case of an emergency, this rule can often be abused. In this video, Joel Schlessinger MD offers his advice on dealing with this office issue. Dr. Joel S